The known and unknown of SGLT2 inhibition in CKD
ISN-WCN 2019 Prof. Carol Pollock explains why there may be benefits of SGLT2 inhibitors in patients with chronic kidney disease, and discusses knowledge gaps in this field.
Video navigation menu
- The knowns and unknowns of SGLT2-i in CKD 00:40
- Mechanisms of benefit of SGLT2-i in CKD 04:42
- Reduced tubular Na+ reabsorption and tubuloglomerular feedback 05:57
- Normalisation of impaired autophagy 08:33
- Shift to a more efficient metabolic substrate 10:21
- Reduced oxidative stress 15:15
- Relative benefits of combined SGLT1/2 inhibitors 16:51
This lecture by prof. Carol Pollock was part of a CME accredited symposium "SGLT2 inhibition in CKD: Discussing the key questions and evidence"
Prof. Carol Pollock, MD, Nephrologist, The University of Sydney School of Medicine, Australia
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: